GlaxoSmithKline PLC (NYSE:GSK) – Equities research analysts at Jefferies Group issued their Q3 2017 earnings estimates for shares of GlaxoSmithKline PLC in a report issued on Tuesday. Jefferies Group analyst J. Holford anticipates that the pharmaceutical company will earn $0.86 per share for the quarter. Jefferies Group also issued estimates for GlaxoSmithKline PLC’s FY2017 earnings at $2.98 EPS and FY2018 earnings at $2.87 EPS.

GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The company had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. ILLEGAL ACTIVITY WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/18/research-analysts-issue-forecasts-for-glaxosmithkline-plcs-q3-2017-earnings-gsk.html.

Other analysts have also recently issued reports about the company. Zacks Investment Research raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a research report on Tuesday, July 18th. Argus reaffirmed a “buy” rating and issued a $50.00 price objective on shares of GlaxoSmithKline PLC in a research report on Thursday, August 31st. TheStreet cut GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, September 21st. Finally, Citigroup Inc. cut GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $44.67.

GlaxoSmithKline PLC (NYSE:GSK) opened at 40.83 on Wednesday. The stock’s 50 day moving average price is $40.35 and its 200-day moving average price is $41.57. GlaxoSmithKline PLC has a one year low of $37.20 and a one year high of $44.54. The firm has a market capitalization of $99.79 billion, a price-to-earnings ratio of 39.56 and a beta of 1.03.

The company also recently declared a quarterly dividend, which was paid on Thursday, October 12th. Investors of record on Friday, August 11th were issued a dividend of $0.491 per share. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a yield of 4.81%. The ex-dividend date of this dividend was Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 198.00%.

A number of large investors have recently added to or reduced their stakes in the stock. 1st Global Advisors Inc. lifted its holdings in GlaxoSmithKline PLC by 0.4% during the 2nd quarter. 1st Global Advisors Inc. now owns 5,271 shares of the pharmaceutical company’s stock worth $227,000 after purchasing an additional 19 shares during the last quarter. Carroll Financial Associates Inc. raised its holdings in GlaxoSmithKline PLC by 0.4% in the 2nd quarter. Carroll Financial Associates Inc. now owns 8,690 shares of the pharmaceutical company’s stock valued at $374,000 after acquiring an additional 35 shares in the last quarter. King Luther Capital Management Corp raised its holdings in GlaxoSmithKline PLC by 1.0% in the 2nd quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock valued at $234,000 after acquiring an additional 55 shares in the last quarter. First National Bank of Omaha raised its holdings in GlaxoSmithKline PLC by 0.3% in the 2nd quarter. First National Bank of Omaha now owns 19,177 shares of the pharmaceutical company’s stock valued at $827,000 after acquiring an additional 57 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its holdings in GlaxoSmithKline PLC by 1.9% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock valued at $137,000 after acquiring an additional 64 shares in the last quarter. 9.28% of the stock is owned by institutional investors and hedge funds.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Earnings History and Estimates for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.